Wound healing is a complex and dynamic biological process that involves the coordinated efforts of multiple cell types and is executed and regulated by numerous growth factors and cytokines. There has been a drivein the past two decades to study the therapeutic effects of various growth factors in the clinical management of non-healing wounds (e.g. pressure ulcers, chronic venous ulcers, diabetic foot ulcers). For this review, we conducted anonline search of Medline and Pub Medicaland critically analyzed the literature regarding the role of growth factors and cytokines in the management of these wounds. Wefocused on currently approved therapies, emerging therapies and future research possibilities. In this reviewwe discuss four growth factors and cytokines currently being used on and off label for the healing of wounds.
INTRODUCTION
Wound healing is a complex, evolutionarily conserved, multi-cellular process aimed towardepitheliumrestoration after injury. Theseprocessesrelyon a multitude of growth factors and cytokines thatexecute and regulate a complex signaling network altering the growth, differentiation, and metabolism of target cells.Duringacute wound healing, these biologically active polypeptides are readily present in the wound bed and play a role in all stages of wound healing: inflammation, formation of granulation tissue, re-epithelialization, matrix formation and re-modeling.However, in vivo and in vitro studies analyzingnon-healing acute and chronic (chronicity defined as physiologically impaired)wounds have demonstrated deregulationofvariousgrowth factors(e.g.platelet derived growth factor (PDGF) (1), vascular endothelial growth factor (VEGF) (2) and basic fibroblast growth factor (bFGF)(3))suggesting a potential target for therapy which has led to a robust interest in using exogenous growth factors and cytokines in the clinical setting to improve clinical outcomes of non-healingwounds.
There is a critical need for new treatments to manage non-healing wounds (e.g. diabetic foot ulcers (DFUs), pressure ulcers (PUs), and chronic venous leg ulcers (VUs)) as they representa major health care burden in the United States. Studies have estimated that there are approximately 71,000 patients with DFUs who undergo limb or digit amputations each year (4) .
Other studies show that advanced stage PUs (stage III and IV) have a mortality rate of 68% (5) and can incur costs for the hospital as high as $124,000 per episode (6) . In addition, non-healing wounds result in prolonged hospital stays (7) , diminished quality of life (8) and increased likelihood of being discharged to a long-term care facility (7) . With the advent of genetic engineering and advances in biological technology, the use of exogenous growth factors and cytokines in treatment of these wounds presents a potential solution to the problem.
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We performed online searches of Medline and Pub Medical using the terms chronic wounds, non-healing wounds, venous ulcers, diabetic ulcers, pressure ulcers, leg ulcers, burn wounds, growth factors and cytokines. The literature regarding the potential role of growth factors in the management of non-healing wounds was reviewed. Clinical studies were critically analyzed with a focus on currently approved therapies, emerging therapies and future research possibilities for the management of non-healingwounds. In this review,we will discuss published literature concerningclinical applications of GM-CSF, PDGF, bFGF, and VEGF.
Granulocyte-macrophage Colony Stimulating Factor
GM-CSF is a cytokine found to be present inthe wound bed after acute injury (9, 10) . GM-CSF has been shown to have important biological effects onwound healing in vivoincluding:
promotion of myofibroblast differentiation andwound contracture facilitation (11); simulation oflocal recruitment of inflammatory cells (12, 13) ; mediation ofepidermal proliferation (14) ; andLangerhans cell recruitment (15) . In addition, GM-CSFalso has the ability to stimulate proliferation and differentiation of hematopoietic progenitor cells making it an effective immune-stimulator (16) (17) (18) (19) (20) (21) . GM-CSF gene knockout animal models show impaired wound healing with reduced neutrophil and macrophage recruitment and reduced vascularization in wounds (22) .While systemic administration of GM-CSF has no effect on wound healing, local applicationhas been shown to enhance wound healing in animal models (23) (24) (25) (26) (27) (28) .
In 1991, the Food and Drug Administration (FDA) approved Sargramostin (Leukine), an injectable recombinant human-GM-CSF (rh-GM-CSF) as an immune-stimulator following chemotherapy and bone marrow transplantation (29) . The FDA specifically approved its use in the following circumstances: following induction of chemotherapy in acute myelogenous leukemia (AML); in mobilization and following transplantation of autologous peripheral blood Accepted Article progenitor cells; in myeloid reconstitution after allogenic bone marrow transplantation, in bone marrow transplantation failure or engraftment delay (16) (17) (18) (19) (20) (21) . Sargramostin comes in a liquid or lyophilized form that requires reconstitution with sterile water and can be administered via subcutaneous injection or intravenous infusion. Dosing depends on the intended therapeutic outcome. Side-effects include slight temperature elevations, swelling, redness and/or discomfort at the site of injection. Sargramostin iscommercially available along with its analog Molgramostim (Leucomax) (29) .
In two randomized controlled studies of chronic VUs,positive effect of rh-GM-CSF was observed (30, 31) .In one study, a single 400 mcgdose of rh-GM-CSF (Leucomax) injection was administered perilesionally in four equal doses in the four quadrants of the wound. Treated patients fared much better than placebo controls prompting early termination of the study. Of the rh-GM-CSF treated patients, 50% completely healed by week 8 as compared to 11% of placebos (30) . In a second double-blind, randomized, placebo-controlled study, chronic VU patients were randomized to placebo or 200 or 400 mcg of rh-GM-GSF (Leucomax). Perilesional injections of the drug were administered in four weekly treatment episodes. Again, there was significant improvement in the healing of wounds in the treatment group. There was no appreciable difference between using 200 or 400 mcg of rh-GM-CSF (31) . The side effect profile in these patients was minimal; with some patients complaining of pain, malaise or discomfort at the injection site. Smaller non-randomized studies of topicalrh-GM-CSF(Leucomax) at concentration of 0.5 to 1.0 mcg/cm^2 applied three times a weekshowed beneficial effects in patients with chronic VUs. A 90% of wounds had complete healing with an average healing time of 19 weeks with no sideeffects. In addition, there was no re-ulceration of the healed ulcer observed after 40 months (32) .
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Efficacy studies of rh-GM-CSF on PUshave yielded diverseresults. Robson antibiotic and insulin therapy, patients receiving G-CSFexperienced earlier eradication of pathogens, shorter hospitalization, shorter duration of antibiotics, and no need for amputation, as compared to placebo. There were no side-effects reported in this study (35) .Diabetic patients commonly fail to develop an appropriate neutrophil response to infection (36) ;therefore improved outcomesin this study were attributed to the potential of G-CSF to increase superoxide Accepted Article production (35) . In a small cohort study of patients with chronic leg ulcers, topical rh-GM-CSF (Leucomax) resulted in complete healingafter 1 month of treatment (37) .
The therapeutic effects of topically applied rh-GM-CSF hydrogel on deep partialthickness burns were confirmed by healing rates in two recent randomized controlled studies.With a dose of 100 mcg/m 2 /day ofrh-GM-CSF hydrogel for the treatment of the burn wound, complete healing of was 100 mcg/m 2 /day. By 28 days all wounds in the treatment group was achieved within 28 days. Therapeutic effects were more obvious in the 14 day time period, followed by 20 days, and 28 days, implying that rh-GM-CSF hydrogel should be applied as early as possible to attain the best therapeutic effect. There were no reported side effects (38, 39) .
Biopsiesobtained from non-healing VUs before and after treatment with intra-dermal injections of GM-CSF were analyzed in an attempt to understand the molecular basis of GM-
CSF. An increase in blood vessel density and vascular endothelial growth factor (VEGF) was found in the wound bed specimens afterGM-CSF administration.This suggested that GM-CSF treatment leadsto increased vascularization and inflammatory cell-derived VEGF may act as an angiogenic mediator in the healing of these ulcers (40) .
Given the literature on the healing effects of rh-GM-CSF and mild side-effect profile, it is routine practice in our clinic to apply Leukine to most physiologically impaired ulcersas an adjunct to debridement and other standard of care therapies when they prove to be refractory to standard treatment. In addition, we have usedLeukine in combination with other growth factors for refractory wounds of all types with variable success. To date, we use a dose of 500µg locally up to two times per week with only one complication recorded in over a thousand of patients treated (41). Larger high quality randomized controlled studies are needed to support the therapeutic efficacy of the rh-GM-CSF for all non-healing wounds.

Platelet Derived Growth Factor
Platelet derived growth factor (PDGF) plays a role in each stage of the wound healing process.PDGF is released from degranulating platelets upon injury and is present in wound fluid (1, 42) .PDGFstimulates mitogenicity and chemotaxis of neutrophils, macrophages, fibroblasts, and smooth muscle cells to the wound site aidingtheinitiation ofthe inflammatory response (43) .In vivo studies demonstrate that PDGF is important in recruiting pericytes and smooth muscle cells to capillaries thus increasing the structural integrity of these vessels (44, 45) .During the epithelialization phase of wound healing, PDGF up-regulates the production of insulin growth factor 1 (IGF-1) and thrombospondin-1 (46) .Furthermore, IGF-1 has been shown to increase keratinocyte motilityand thrombospondin-1, which protectsproteolytic degradation of PDGF and promotesfibroblast growth in vitro in a dose-dependent manner (47) .PDGF also enhances proliferation of fibroblasts and consequently the production of ECM (48), induces the myofibroblast phenotype in these cells and stimulates fibroblasts to construct collagen matrices (49) .PDGF is decreased in chronic wounds due to itssusceptibilityto the proteolytic environment found in the chronic wound.(50, 51)
In 1997, the FDA approved Becaplermin (Regranex) for the treatment of DFUs that extend into the subcutaneous tissue or beyond and have adequate blood supply (52) .Becaplermin is a recombinant human-PDGF (rh-PDGF-BB) that has been shown to accelerate wound closure in DFUsin randomized clinical trials (53) (54) (55) (56) .In a multicenter double-blind placebo-controlled trial in patients with type 1or type 2 diabetes and chronic ulcers of at least 8 week duration, 100ug/g of Becaplermin significantly increased the incidence of complete wound closure by 43%
and decreased the time to achieve complete wound closure by 32% when compared to placebo (54 Similarly,Becaplermin was linked to a significant reduction in amputations (58).Data from this study was consistent with data from the randomized controlled trials.
Commonly observed adverse reactions to Becaplermin topical application include erythematous rashes and aburning sensation at the site of application (55) .More serious adverse eventssuch as osteomyelitis and cellulitisare reported less frequently (56) .Data prompting the FDA to release a warning of malignancy risk associated with Becaplermin use remains anecdotal (57) .A20-month follow up study from two randomized controlled trials revealed an increased risk of malignancy with Becaplermin. In the Becaplermin group, the frequency of new cancer was 3% compared with 1% in the control group. In a larger patient database study, the incidence of cancer or cancer related mortality was not increased with Becaplermin treatment compared with the control group(52). However, patients who had been treated with more than three tubes of Becaplerminshowedincreased cancer risk (51) . In both studies, there was no association with any particular type of malignancy and all cancers were remote from the treatment site (51, 52) . .In a double blind study, patients with advanced stage PUs were randomized to receive placebo, or 100mcg/g or 300mcg/g of Regranex gel once daily until theyachievedcomplete healing or for 16 weeks. Use of the gel at 100mcg/g and 300mcg/g significantly increased the incidence of complete and 90% healing and reduced the median relative ulcer volume at endpoint compared with placebo. The adverse reactions described in this study included rash, erythema and fever; however, these events were attributed to the underlying disorder and age of the patients (60).
Topical application of PDGF to VUs has been attempted with minimal efficacy (61).The reasons for failed efficacy may be due to problems in growth factor penetration into the wound, without which the growth factor cannot reach its target cell. This is further complicated by the fact that growth factor application often requires daily treatmentthat interrupts the use of standard limb compression (61) .The use of gene transfer to introduce PDGF into animal wounds demonstrated superior results to topical application (62) (63) (64) (65) (66) . In one study peri-ulcer injection of a replication-incomplete adenoviral construct expressing PDGF was injected into patients with chronic VUs. The injection was well tolerated with no reports of erythema or pain. 73% of patients showedevidence of wound healing after 4 weeks; however, this percentage dropped to 47% at 24 weeks of care. It was noted that patients did not consistently wear limb compression during this time, suggesting that unless a patient wears their compression dressing they are unlikely to heal(62).
In the clinical setting there is evidence that rh-PDGF is effective in the healing of DFUs that extend beyond the level of the subcutaneous tissue (55) . However, given the cost and its variability in number needed to treat to achieve healing, it is a reasonable choice in those wounds which have not healed after optimal conservative treatment. In addition, there is also benefit to 
Fibroblast Growth Factor
Within the fibroblast growth factor family(FGF), FGF-2, FGF-7 and FGF-10 have been
shown to be integral in cutaneous wound healing. FGFs are produced by keratinocytes,
fibroblasts, endothelial cells, smooth muscle cells, chondrocytes, and mast cells (67-72).FGF-2 or basic FGF (bFGF) is increased in acute wounds and plays a role in granulation tissue
formation, re-epithelialization and tissue remodeling (73) .In vitro studies have demonstrated that FGF-2 regulates the synthesis and deposition of various EMC components, increases keratinocyte motility during re-epithelialization (74-76), promotes the migration of fibroblasts and stimulates them to produce collagenase (77) . Levels of FGF-2 are decreased in chronic wounds (50).
Recombinant human-bFGF (rh-bFGF) topical application has shown some promise in the management of PUs. In one randomized controlled trial, patients with PUs (stage III/IV) were randomized to receive placebo or rh-bFGF at varyingdoses (1mcg/cm 2 , 5 mcg/cm 2 ,10 mcg/cm 2 ).
When all subgroups were combined, comparison showed a general trend toward increased healing over time. In addition, when assessed histologically, rh-bFGF-treated wound tissuedemonstrated increased number of fibroblasts and capillaries. More patients in the treatment group achieved >70% wound closure (78) .The positive effect in PUs can be seen with
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statistical significance ina more recent study by Robson Et al. wherethe effects of a combination of growth factor therapies on PU healing were compared. This trial found that wounds treated withrh-bFGF had better healing ratesthan rh-bFGF and rh-GM-CSF together and rh-GM-CSF treatment alone when compared to placebo. In this study, rh-bFGF was applied at a dose of5.0 mcg/cm 2 (33). In a case control study, treatment of PUs with rh-bFGF accelerated wound healing over time when compared to control with respect to volume ofexudate, ulcer depth, granulation tissue formation and epithelialization (79) .A study examining the long term outcomes of use of rh-bFGF in PUs found that 84.6% of patients who received rh-FGF and achieved ≥85%
healingduring the treatment phase remained healed after 1 year (80).
The effect of rh-bFGF on DFU management showed more variable effect. In arandomized controlled trial, patients with diabetic ulcers on the plantar surface of the foot were randomized to receive topically applied rh-bFGF or placebo. The wounds were Wagner grade 1-3 and more than 0.5 cm in largest diameter. A concentration of 5mcg/mL rh-bFGF or placebo was applied daily for 6 weeks and then twice a week for thefollowing 12 weeks. After the study period there was no difference between healing rates for patients receiving rh-bFGF or placebo (81) .More recently,a randomized controlled clinical trial conducted by Uchi Et al. with patients suffering from non-ischemic diabetic ulcers with a Wagner grade of 2 and measuring 900 mm 2 or less were randomized to placebo or treatment with 0.001% (50 mcg) rh-bFGF and 0.01% (500mcg) rh-bFGF for up to 8 weeks. Differences in healing were significant. Ulcerstreatedwith 0.01% rh-bFGFshowed a75% or greater reduction in the area of the ulcer compared to placebo (82) .
Treatment with bFGF has demonstrateda positive effect in second degree burns. In one randomized controlled trial, patients with superficial and deep second degree burns were Accepted Article randomized to receive placebo or daily topical recombinant bovine bFGF (rb-bFGF). All patients treated with rb-bFGF had faster granulation tissue formation and epidermal regeneration than those in the placebo group. Superficial and deep second-degree burns treated with rb-bFGF healed in a mean of 9.9 days and 18.0 days respectively, which was significantly better than the placebo group (83) .Topical oxygen therapy supplementing bFGF application accelerated deep second-degree burn healing (84) . In addition, the use of bovine amnion in conjunction with topical rb-bFGF was found to decrease healing time for deep partial thickness burn wounds (85) .In anobservational study in rats, treatment of deep partial thickness burn wounds using gene 
Repifermin, a recombinant human KGF-2 has been used clinically with mixed results. A randomized, double blind, parallel group placebo controlled multi-center study was conducted to evaluate the safety and efficacy of topical Repifermin treatment for 12 weeks, in the healing of chronic VUs. Repifermin accelerated wound healing; with significantly more patients achieving 75% wound closure in the treatment group over placebo (89) . While other non-healing wounds such as PUs and VUs may benefit from exogenous VEGF administration given that they have local areas of ischemia, randomized controlled trials for treatment in these wounds havenot been conducted to date.
Proteases
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The milieu of the chronic wound not only contains reduced levels of many growth factor important for wound healing, but also has been shown to have an imbalance between collagenolytic activity and endogenous inhibitors. Such harsh environment of high protease activity represents a challenge in sustaining presence of growth factors and cytokines. It has been demonstrated that there is rapid degradation of exogenous growth factor when applied to chronic wounds. In one study, exogenous TGF-B and PDGF were incubated with fluid from venous stasis ulcers, pressure ulcers and acute surgical wounds. There was significant degradation of these growth factors in the chronic wounds. In particular, there was a correlation between the level of neutrophil elastase and degradation, with those wounds expressing greater levels of elastase having more degradation. Furthermore, applying an inhibitor to neutrophil elastase blocked degradation. (114) Matrix metalloproteases, specifically MMP-2 and MMP-9 have also been shown to be elevated in chronic wounds. (115, 116) . One study looked at acute surgical wounds and nonhealing pressure ulcers and found elevated levels of MMP-2 and MMP-9 on the order of 10-fold and 25-fold respectively in the non-healing pressure ulcers. In addition, this study demonstrated that there were elevated levels of collagenolytic activity in the non-healing pressure ulcers.
(116).The abundance of activated proteases is synergized with abnormally low levels of protease inhibitors. One study showed that tissue inhibitor of metalloproteases-1 is decreased in chronic wounds. (117) . Given these findings simply adding an exogenous growth factor to a chronic wound is not enough for successful healing to occur. Application of protease inhibitors in combination with wound debridement could create a microenvironment that is more suitable for growth factor activity.
Debridement
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Prior to the application of any exogenous growth factor, the target wound should be sharply debrided. Cells grown from the non-healing edge of a wound have diminished capacity to migrate or respond to wound healing stimuli, whereas the cells derived from the adjacent, nonulcerated area of the wound showed increased capacity to migrate and responded well to woundhealing stimuli (118) . Accepted Article
